This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CTSD | |
|---|---|
| Name | Cathepsin D |
| Organism | Homo sapiens |
| Uniprot | P07339 |
| Gene | CTSD |
| Location | Chromosome 11p15.5 |
CTSD is a human gene encoding the lysosomal aspartic protease Cathepsin D, a ubiquitous endopeptidase implicated in proteolytic processing, antigen presentation, and apoptosis. The protein has conserved roles across metazoans and is studied in contexts ranging from neurodegeneration to cancer metastasis. CTSD research intersects with studies of lysosomal biology, protein trafficking, and protease inhibitor therapeutics.
The CTSD gene is located at 11p15.5 and consists of multiple exons producing a preproenzyme precursor processed into a mature heavy-chain/light-chain heterodimer. Genomic mapping studies reference loci found in cytogenetic surveys and somatic mutation screens performed in cancer cohorts from institutions like the National Institutes of Health and sequencing efforts comparable to the Human Genome Project. The preprocathepsin D contains a signal peptide, a propeptide that maintains zymogen latency, and an active site characterized by two conserved aspartate residues typical of the peptidase A1 family. Structural characterization includes X-ray crystallography determinations that relate to catalytic mechanisms analyzed in comparison with orthologs studied in Drosophila melanogaster, Mus musculus, and Caenorhabditis elegans. Protein domain databases cross-reference entries for the signal peptide, propeptide, and mature protease regions used by groups at institutions such as Cold Spring Harbor Laboratory and Max Planck Institute.
Cathepsin D functions as an endolysosomal aspartic protease involved in bulk protein turnover, maturation of lysosomal proteins, and regulated proteolysis of signaling peptides. Biochemical assays developed in laboratories affiliated with Harvard Medical School, Stanford University, and University of Cambridge measure activity using fluorogenic substrates and pH-dependent kinetics reflecting optimal activity at acidic pH. CTSD participates in the cleavage of prohormones and APP processing, which has been investigated by teams associated with Massachusetts Institute of Technology and Columbia University. Its proteolytic activity contributes to apoptosis pathways explored in studies linked to Max Delbrück Center and is modulated by endogenous inhibitors and small-molecule drugs examined in pharmaceutical research at companies like Roche and Pfizer.
CTSD expression is regulated transcriptionally by factors identified in promoter analyses, including hormone-responsive elements responding to estrogens studied in clinical research at Mayo Clinic and glucocorticoids analyzed by investigators at Johns Hopkins University. Post-translational regulation involves mannose-6-phosphate tagging for trafficking through the Golgi apparatus to lysosomes, a pathway detailed in cell biology work from Yale University and University of California, San Francisco. Tissue expression profiling from consortia such as the Genotype-Tissue Expression project and datasets generated at Salk Institute show high expression in brain, liver, and immune tissues, with inducible expression observed in macrophages during responses characterized by labs at Rockefeller University.
Altered CTSD activity is associated with diverse pathologies including neurodegenerative disorders, breast cancer, and lysosomal storage diseases. Reduced CTSD function is implicated in neuronal ceroid lipofuscinosis forms elucidated in cohort studies coordinated with European NCL Consortium and patient registries overseen by National Organization for Rare Disorders. Elevated CTSD expression and secretion are correlated with poor prognosis in breast cancer studies published by groups at Memorial Sloan Kettering Cancer Center and metastasis research linked to The Institute of Cancer Research. CTSD involvement in APP processing ties to research in Alzheimer's disease funded through collaborations including Alzheimer's Association and university centers such as University College London.
Pathogenic variants in CTSD include missense and loss-of-function mutations that disrupt maturation or catalytic residues; these have been cataloged in clinical variant databases curated by organizations like ClinVar and research consortia analyzing exome sequencing from cohorts including the 1000 Genomes Project and Exome Aggregation Consortium. Specific mutations affecting the active site aspartates or propeptide cleavage sites have been modeled in murine knockouts developed by groups at National Cancer Institute and in patient-derived fibroblasts studied at Charité – Universitätsmedizin Berlin.
CTSD interacts with lysosomal membrane proteins and trafficking receptors such as the mannose-6-phosphate receptor studied in cell trafficking research at Weizmann Institute of Science and endosomal sorting complexes probed by teams at European Molecular Biology Laboratory. It participates in pathways including autophagy-lysosome flux characterized by collaborations involving Gordon Center for Medical Imaging and apoptosis signaling intersecting with caspase networks analyzed by investigators at Dana-Farber Cancer Institute.
Experimental approaches encompass CTSD knockout mice generated by laboratories at Jackson Laboratory and transgenic overexpression models used to study cancer phenotypes at Fred Hutchinson Cancer Research Center. In vitro methods include activity assays, zymography, and mass spectrometry proteomics developed by centers like Broad Institute and imaging of lysosomal dynamics via live-cell microscopy protocols from Cell Biology Core Facility groups. Gene editing using CRISPR-Cas9 and RNAi strategies have been applied across model systems including cultured human neurons derived from induced pluripotent stem cells used in collaborations with Stanford Neurosciences Institute.
Category:Human proteins